Contents

COVID-19 vaccination in Switzerland

Plan to immunize against COVID-19

This article needs to be updated. Please help update this article to reflect recent events or newly available information. (May 2021)

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

By 14 November 2023, 17,015,053 doses of COVID-19 vaccine have been administered.^[1]

Background[edit]

On 19 December 2020, the Swiss Agency for Therapeutic Products (Swissmedic) approved the Pfizer–BioNTech COVID-19 vaccine (Comirnaty) for regular use, two months after receiving the application, although it was expected to give a decision later than other European countries, as Swiss laws do not allow emergency approvals. After the application was processed with high priority using all the available resources, the head of Swissmedic stated that the vaccine fully complied with the requirements of safety, efficacy, and quality. This constituted the first authorization by a stringent regulatory authority under a standard procedure for any COVID-19 vaccine.^[2][3] Three days later, 107 000 vaccine shots were received by the army to be dispatched in the cantons. On 23 December, 302 days after the first official case, the first patient, a 90-year-old woman from Central Switzerland, was vaccinated in a retirement home in Lucerne.^[4] On that day, the cantons of Lucerne, Zug, Schwyz, Nidwalden and Appenzell Innerrhoden launched the vaccination campaign,^[5] marking the beginning of mass vaccination in Switzerland and continental Europe outside Russia.^[6] Most cantons followed by 4 January 2021 and all the rest of them by 11 January. By that day, about 0.5% of the population received the Pfizer–BioNTech COVID-19 vaccine.^[7]

On 12 January 2021, Swissmedic approved the second COVID-19 vaccine: the mRNA-1273 made by Moderna.^[8][9] The Lonza Group where the vaccine is produced was visited by Federal Councilor Alain Berset the previous day. Up to 800,000 vaccines per day are expected to be produced there. A year after the first COVID-19 outbreak, the number of vaccinated people largely outnumbered the official cases. On 7 March, about 10% of the population received at least one shot of the two approved vaccines (Pfizer and Moderna) and about 3% were fully vaccinated.^[10]

A third vaccine, the Oxford/AstraZeneca vaccine (AZD1222), which comprised 5.3 million of the doses ordered by Swiss authorities, was rejected for approval by the Swiss medical authority, SwissMedic, citing insufficient data.^[11]

In March 2021, the Swiss Federal Health Ministry reported that approved vaccine deliveries have increased steadily every month. Switzerland received 1.1 million doses of the Moderna and Pfizer vaccines in January and February 2021, and another 1 million vaccine doses in March, exceeding initial expectations. As of 14 November, there have been 6,123,678 people who have taken the first dose of coronavirus vaccine.^[12][13] The country plans to have its 8.6 million residents vaccinated by summer 2021.^[14]

In April 2021, there were reports that vaccine administration and production efforts at the Lonza Group plant in Visp have been hampered due to overly stringent immigration rules in Switzerland, reducing the influx of qualified biotech and healthcare workers, particularly with regard to non-EU/EFTA states. The Valais National Council urged the Swiss federal authorities to create exemptions from the current immigration rules for essential biotech industries.^[15]

Vaccines on order[edit]

Vaccine	Approval	Deployment
Pfizer–BioNTech	December 19, 2020	Yes
Moderna	January 12, 2021	Yes
Janssen	March 22, 2021	Yes
Novavax	April 13, 2022	Yes

References[edit]